STE-ACS冠脉支架植入治疗前后血液T细胞亚群CD3、CD4、CD8的水平变化及其意义-现代医学

STE-ACS冠脉支架植入治疗前后血液T细胞亚群CD3、CD4、CD8的水平变化及其意义

单位：青海省第五人民医院心血管内科, 青海西宁 810001

分类号：R541.4

出版年·卷·期（页码）：2017·36·第九期（1291-1294）

摘要：

目的：探讨ST段抬高型急性冠脉综合征（STE-ACS）冠脉支架植入治疗前后T细胞亚群变化及其意义。方法：选取2014年1月至2016年3月在我院治疗的STE-ACS患者74例（病例组），同时选取健康志愿者80例作为对照组，检测两组外周血T淋巴细胞亚群水平。结果：病例组CD3⁺、CD4⁺和CD4⁺/CD8⁺分别为（0.622±0.070）%、（0.324±0.057）%和（0.987±0.122），明显低于对照组（P<0.05），而CD8⁺为（0.330±0.031）%，明显高于对照组（P<0.05）；病例组术后1周和2周CD3⁺、CD4⁺和CD4⁺/CD8⁺均较术前明显增加（P<0.05），而CD8⁺较术前明显降低（P<0.05）；根据TMP心肌灌注分级标准，冠脉支架植入1周后TMP 2~3级患者CD3⁺、CD4⁺和CD4⁺/CD8⁺分别为（0.731±0.050）%、（0.424±0.037）%和（1.763±0.109），明显高于TMP 0~1级组（P<0.05）。结论：STE-ACS患者外周血T细胞亚群异常，冠脉支架植入术后T淋巴细胞亚群明显改善。

Objective: To investigate the changes and significance of T cell subsets in patients with ST segment elevation acute coronary syndrome (STE-ACS) before and after coronary stent implantation. Methods: 74 patients with STE-ACS were selected in our hospital from January 2014 to March 2016, and healthy volunteers were selected as control group (n=80), the levels of T lymphocyte subsets in peripheral blood of the two groups were detected. Results: The CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in the cases group were (0.622±0.070)% and (0.324±0.057)% and (0.987±0.122), significantly lower than those in the control group (P<0.05), and CD8⁺ was (0.330±0.031)%, significantly higher than that in the control group (P<0.05); Compared with preoperation, the CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in the case group at 1 and 2 weeks after operation were significantly increased(P<0.05), but CD8⁺ was significantly lower than that prior to surgery (P<0.05); According to TMP myocardial perfusion grading standard, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ of patients with TMP 2-3 grade at 1 weeks after coronary stenting were (0.731 ±0.050)%, (0.424 ±0.037)% and (1.763 ±0.109), which were significantly higher than those in TMP 0-1 grade group (P<0.05). Conclusion: T lymphocyte subsets in peripheral blood of patients with STE-ACS are abnormal, and the T lymphocyte subsets are improved significantly after coronary stent implantation.

参考文献：

[1] 吕汉叶.急性冠状动脉综合征患者血清sol-CXCL16的表达规律[J].东南大学学报:医学版,2016,35(5):709-713.
[2] 侯建同,朱伯谦,孔庆玲,等.替罗非班对急性冠脉综合征合并代谢综合征介入治疗患者的有效性及安全性研究[J].东南大学学报:医学版,2016,35(5):759-762.
[3] 霍勇,葛均波,韩雅玲,等.急性冠状动脉综合征患者强化他汀治疗专家共识[J].中国介入心脏病学杂志,2014,22(1):4-6.
[4] 龚天奎,陈月云.淋巴细胞亚群与冠状动脉粥样硬化性心脏病关系研究进展[J].中国免疫学杂志,2015,31(7):992-995.
[5] 刘亚丽,许晓伟,苏维芳.国产瑞舒伐他汀与阿托伐他汀对行择期经皮冠状动脉介入的急性冠状动脉综合征患者疗效的随机对照研究[J].山西医药杂志,2016,45(4):436-438.
[6] PFEFFER M A,CLAGGETT B,DIAZ R,et al.Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J].N Engl J Med,2015,373(23):2247-2257.
[7] SANTOSGALLEGO C G,PICATOSTE B,BADIMON J J.Pathophysiology of acute coronary syndrome[J].Curr Atheroscler Rep,2014,16(4):1-9.
[8] 吴慧慧,周建华.心电图对非ST段抬高型急性冠状动脉综合征患者危险分层中的临床价值[J].中国医学装备,2016,13(12):115-117.
[9] 郑昊钏,龙芳,杨华,等.急性冠脉综合征的发病机制及治疗进展[J].中国药房,2014,25(30):2846-2848.
[10] 何华亮,王芬,张页,等.血管炎性反应在急性冠脉综合征发病机制中的作用[J].武警医学,2014,25(9):875-877.
[11] 马飞,李毅,于学忠.免疫反应在急性冠脉综合征发病机制中的研究新进展[J].中华急诊医学杂志,2015,24(10):1181-1183.
[12] 徐林杰,吴继雄.调节性T细胞在急性冠脉综合征中的研究进展[J].安徽医药,2014,18(3):415-418.
[13] 陈西洲.血清炎症因子在冠心病斑块易损程度的预测价值[J].中国临床医生杂志,2015,44(9):41-43.
[14] 邹筱冬,吴同果,崔进,等.早期强化瑞舒伐他汀治疗对急性冠状动脉综合征患者经皮冠状动脉介入术后心肾功能的影响[J].广西医学,2014,36(6):760-763.
[15] 郑俊晨,马晓媛,高波,等.冠状动脉介入术后再狭窄的影响因素研究[J].实用心脑肺血管病杂志,2016,24(2):16-19.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录